Skip to main content
Equibles
PLYX logo

PLYX · Polaryx Therapeutics, Inc.

Track PLYX — free

Use PLYX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research PLYX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$2.01 +0.01 (+0.25%)
Rebalance outlook locked
Going-concern doubt — flagged Aug 13, 2026

Substantial doubt about the company's ability to continue as a going concern.

“These matters, along with the conditions described above, raise substantial doubt about the Company's ability to continue as a going concern for a period of twelve months from the date these financial statements were available to be issued.”
View the 10-Q filed Aug 13, 2026
Market Cap
$99.69M
Shares
49.85M
Volume · Oct 12 15.56K Avg daily vol (3M) 75.64K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$2.00 Open$2.00 Day$1.98–2.03 Available close range$1.87–35.00 Avg vol 30d36K Short int143K · 0.3% float · 4.5d Short vol39% DataFeb 2026–Oct 2026 Filing10-Q · Aug 13

The closing range uses available history since Feb 2, 2026; less than a full year is stored.

Up next

Latest filing: 10-Q
filed Aug 13, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$6.85M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$11.54M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+8.1%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
0.3%
Latest settlement · 4.5 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Neutral Fundamentals Limited Quant / Vol Very High
Market backdrop VIX 14.8 · calm Equity put/call 0.56
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 50-day avg −5%
below
RSI (14) 43
neutral
MACD trend Negative
52-week position 0%
near low
Momentum
relative strength
Very Weak
1-month return −1%
trailing
6-month return −65%
trailing
Relative strength −75%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50/200-day averages unavailable
Institutional flow Distributing
-7% holders QoQ · +4 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.29% of float · ▼ -23.3% MoM · 4.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
13 holders — 13F breadth
Squeeze score 39
low risk · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Very High
Volatility 200%
annualized · 1-yr
Max drawdown −95%
past year
ATR 6.1%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Sell
3 · 2 · 0
50 / 200-day cross
No cross Neutral
Price vs 50-day avg
−5% Bearish
RSI (14)
43 Neutral
MACD trend
Negative Bearish
52-week position
0% Bearish
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50/200-day averages unavailable
Institutional flow Distributing
-7% holders QoQ · +4 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.29% of float · ▼ -23.3% MoM · 4.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
13 holders — 13F breadth
Price context
position in its available closing range
Range low $2 Now $2 · 0% Range high $35
vs 50-day avg -5%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
PLYX
Polaryx Therapeutics, Inc.
this stock
$99.69M — — — 0.3%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $129.29B +12.5% +46.2% 29.7 1.8%
MRNA
Moderna, Inc.
 $89.83B +663.0% +4.3% — 7.7%
REGN
Regeneron Pharmaceuticals, Inc.
 $76.86B -3.3% +20.8% 18.5 2.1%
CSLLY
Csl Ltd
 $61.77B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
13
% held
4.4%
Net QoQ
-74.0K sh
Top holder
VANGUARD CAPITAL MANAGEME…
Held Float
View
Held by Funds
Fund positions
9
View
Short & Settlement
Short Interest Falling
Shares short
143.3K
Days to cover
4.5d
Change
-43.4K sh
View
Short Volume
Short vol %
39%
As of
Oct 9, 2026
Short Total
View
Fails to Deliver
FTD shares
1.6K
Value
$3.1K
As of
Sep 11, 2026
View
Off-Exchange
Off-exchange %
47.6%
Week of
Sep 7, 2026
Off-exch Lit
View
Financials
Financials
Net income (FY)
$-9.0M
EPS diluted
$-0.20
View
Filings
SEC Filings
Latest
8-K
Filed
Sep 14, 2026
This year
10
View
Earnings & Events
Webcasts
Last webcast
Apr 16, 2026
View

Performance

5D 20D 120D MTD YTD
PLYX -3.9% -0.5% -64.9% -3.4% —
SPY +1.2% +1.9% +9.9% +2.1% +14.2%
vs SPY -5.0% -2.4% -74.8% -5.5% —
Key facts CIK 2075320 CUSIP 73110F100 13F (30d) 1 filings 1 filers Visit website Investor relations